Cargando…

Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients

PURPOSE: To evaluate the efficiency and efficacy of corifollitropin alfa (follicle-stimulating hormone–carboxy terminal peptide) in the treatment of poor responder patients. METHODS: A total of 85 poor responder patients with a mean age 40.2±3.9 years entered our assisted fertilization program. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Selman, Helmy, Rinaldi, Leonardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074728/ https://www.ncbi.nlm.nih.gov/pubmed/27799826 http://dx.doi.org/10.2147/IJWH.S117577

Ejemplares similares

Corifollitropin alfa for poor responders patients, a prospective randomized study
por: Fusi, F. M., et al.
Publicado: (2020)

Comparison of corifollitropin alfa and daily recombinant follicle-stimulating hormone in poor responder patients undergoing in vitro fertilization cycles
por: Akarsu, Süleyman, et al.
Publicado: (2017)

Corifollitropin Alfa for Controlled Ovarian Stimulation in Assisted Reproductive Technologies: State of the Art
por: Carvalho, Bruno Ramalho de
Publicado: (2023)

The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist
por: Seyhan, Ayse, et al.
Publicado: (2011)

Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity
por: Norman, Robert J., et al.
Publicado: (2011)

Cumulative Live Birth Rates Following Stimulation With Corifollitropin Alfa Compared With hp-hMG in a GnRH Antagonist Protocol in Poor Ovarian Responders
por: Errázuriz, Joaquín, et al.
Publicado: (2019)

A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders
por: Wang, Huai-Ling, et al.
Publicado: (2016)

Evaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol
por: Salgueiro, Lister L., et al.
Publicado: (2016)

Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis
por: Fensore, Stefania, et al.
Publicado: (2015)

Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles
por: Oehninger, Sergio, et al.
Publicado: (2015)

Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial
por: Leader, Arthur, et al.
Publicado: (2013)

Conventional ovarian stimulation vs. delayed single dose corifollitropin alfa ovarian stimulation in oocyte donors: a prospective randomized study. Tail trial
por: Alvarado Franco, Carlos Alberto, et al.
Publicado: (2023)

Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction
por: Souza, Priscila Morais Galvão, et al.
Publicado: (2017)

Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol
por: Griesinger, Georg, et al.
Publicado: (2016)

A new approach for ovarian stimulation in IVF using Corifollitropin Alfa in combination with GnRH analogues to trigger final oocyte maturation. A pilot study
por: Decleer, W., et al.
Publicado: (2014)

Corifollitropin α followed by menotropin for poor ovarian responders’ trial (COMPORT): a protocol of a multicentre randomised trial
por: Polyzos, Nikolaos P, et al.
Publicado: (2013)

Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study
por: Barrenetxea, Gorka, et al.
Publicado: (2018)

Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol
por: Huang, Ting-Chi, et al.
Publicado: (2021)

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders
por: Humaidan, P., et al.
Publicado: (2017)

A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol
por: Devroey, P., et al.
Publicado: (2009)

Corifollitropin alfa vs recombinant FSH for controlled ovarian stimulation in women aged 35–42 years with a body weight ≥50 kg: a randomized controlled trial
por: Vuong, N L, et al.
Publicado: (2017)

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders
por: Humaidan, P., et al.
Publicado: (2017)

Efficacy of corifollitropin alfa followed by recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist protocol for Korean women undergoing assisted reproduction
por: Park, Hyo Young, et al.
Publicado: (2015)

Association of progesterone production with serum anti-Müllerian hormone levels in assisted reproductive technology cycles with corifollitropin alfa
por: Lee, Tsung-Hsien, et al.
Publicado: (2018)

Luteal phase ovarian stimulation for poor ovarian responders
por: Zhang, Wei, et al.
Publicado: (2018)

Comparison of mild ovarian stimulation with conventional ovarian stimulation in poor responders
por: Yoo, Ji Hee, et al.
Publicado: (2011)

Profile of follitropin alpha/lutropin alpha combination for the stimulation of follicular development in women with severe luteinizing hormone and follicle-stimulating hormone deficiency
por: Rinaldi, Leonardo, et al.
Publicado: (2016)

Ovarian stimulation modalities in poor responders
por: ÖZKAN, Zehra Sema
Publicado: (2019)

An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism
por: Nieschlag, Eberhard, et al.
Publicado: (2017)

Evaluation of the safety and efficacy of corifollitropin alfa combined with GnRH agonist triggering in oocyte donation cycles. A prospective longitudinal study
por: Tsakiridis, Ioannis, et al.
Publicado: (2020)

Corifollitropin alfa versus follitropin beta: an economic analysis alongside a randomized controlled trial in women undergoing IVF/ICSI
por: Khoa, Le Dang, et al.
Publicado: (2020)

Individualized controlled ovarian stimulation in expected poor-responders: an update
por: Haahr, Thor, et al.
Publicado: (2018)

Corifollitropin alpha, clomiphene citrate and dydrogesterone without daily gonadotrophin: a new option of a friendly protocol for high-responder oocyte donors
por: de Melo, Anderson Sanches, et al.
Publicado: (2022)

What Is the Best Regimen for Ovarian Stimulation of Poor Responders in ART/IVF?
por: Blumenfeld, Zeev
Publicado: (2020)

ANDRO-IVF: a novel protocol for poor responders to IVF controlled ovarian stimulation
por: Bercaire, Ludmila, et al.
Publicado: (2018)

Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development
por: Abramova, Nadezda, et al.
Publicado: (2018)

Luteal phase ovarian stimulation following oocyte retrieval: is it helpful for poor responders?
por: Zhang, John
Publicado: (2015)

Double or dual stimulation in poor ovarian responders: where do we stand?
por: Polat, Mehtap, et al.
Publicado: (2021)

Predicting IVF outcome in poor ovarian responders
por: Lebovitz, Oshrit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_slvkk6vepdb5seopnb5h8fuddl